About Voltage-gated inwardly rectifying potassium channel KCNH3
Voltage-gated inwardly rectifying potassium channel KCNH3 (KCNH3) is a protein
from Homo sapiens identified by UniProt accession
Q9ULD8, 1083 residues long.
MolForge cross-references it against 0 known binders and
182 disease associations.
Target properties
| Protein name | Voltage-gated inwardly rectifying potassium channel KCNH3 |
|---|
| UniProt accession | Q9ULD8 |
|---|
| Gene | KCNH3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1083 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (182)
Diseases linked to this target (Open Targets).
- multiple sclerosis · score 0.59
- Myasthenia gravis · score 0.57
- Muscle weakness · score 0.46
- small cell carcinoma · score 0.46
- secondary progressive multiple sclerosis · score 0.43
- primary progressive multiple sclerosis · score 0.37
- anterior ischemic optic neuropathy · score 0.37
- transverse myelitis · score 0.37
- atrial flutter · score 0.35
- atrial fibrillation · score 0.35
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9ULD8-F1 | alphafold | PREDICTED | 64.02 | — |
Amino-acid sequence (1083 residues)
MPAMRGLLAP QNTFLDTIAT RFDGTHSNFV LGNAQVAGLF PVVYCSDGFC DLTGFSRAEV MQRGCACSFL YGPDTSELVR QQIRKALDEH KEFKAELILY RKSGLPFWCL LDVIPIKNEK GEVALFLVSH KDISETKNRG GPDRWKETGG GRRRYGRARS KGFNANRRRS RAVLYHLSGH LQKQPKGKHK LNKGVFGEKP NLPEYKVAAI RKSPFILLHC GALRATWDGF ILLATLYVAV TVPYSVCVST AREPSAARGP PSVCDLAVEV LFILDIVLNF RTTFVSKSGQ VVFAPKSICL HYVTTWFLLD VIAALPFDLL HAFKVNVYFG AHLLKTVRLL RLLRLLPRLD RYSQYSAVVL TLLMAVFALL AHWVACVWFY IGQREIESSE SELPEIGWLQ ELARRLETPY YLVGRRPAGG NSSGQSDNCS SSSEANGTGL ELLGGPSLRS AYITSLYFAL SSLTSVGFGN VSANTDTEKI FSICTMLIGA LMHAVVFGNV TAIIQRMYAR RFLYHSRTRD LRDYIRIHRI PKPLKQRMLE YFQATWAVNN GIDTTELLQS LPDELRADIA MHLHKEVLQL PLFEAASRGC LRALSLALRP AFCTPGEYLI HQGDALQALY FVCSGSMEVL KGGTVLAILG KGDLIGCELP RREQVVKANA DVKGLTYCVL QCLQLAGLHD SLALYPEFAP RFSRGLRGEL SYNLGAGGGS AEVDTSSLSG DNTLMSTLEE KETDGEQGPT VSPAPADEPS SPLLSPGCTS SSSAAKLLSP RRTAPRPRLG GRGRPGRAGA LKAEAGPSAP PRALEGLRLP PMPWNVPPDL SPRVVDGIED GCGSDQPKFS FRVGQSGPEC SSSPSPGPES GLLTVPHGPS EARNTDTLDK LRQAVTELSE QVLQMREGLQ SLRQAVQLVL APHREGPCPR ASGEGPCPAS TSGLLQPLCV DTGASSYCLQ PPAGSVLSGT WPHPRPGPPP LMAPWPWGPP ASQSSPWPRA TAFWTSTSDS EPPASGDLCS EPSTPASPPP SEEGARTGPA EPVSQAEATS TGEPPPGSGG LALPWDPHSL EMVLIGCHGS GTVQWTQEEG TGV
Explore Voltage-gated inwardly rectifying potassium channel KCNH3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets